Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Menactra, a quadrivalent (a, c, y, and w135) meningococcal conjugate vaccine (MCV4), was licensed in the United States on January 14, 2005. Each 0.5mL dose of MCV4 contains 4g of each capsular polysaccharide from Neisseria meningitidis serogroups A, C, Y, and W135 conjugated to 48g of diphtheria toxoid.

Guillain-Barré Syndrome and Menactra Meningococcal Conjugate Vaccine